Poland - Pharmaceutical products

Description

The subject matter of the contract is the successive supply of a medicinal product used in chemotherapy for patients of the Provincial Specialist Hospital in Legnica, described in detail in Appendix No. 2A to the ToR, which constitutes its integral part.2Quality standards referred to in Art. 91 sec. 2a of the Public Procurement Law - the Contracting Authority requires the supply of medicinal products with a strictly defined qualitative and quantitative composition - the subject matter of the contract has been described using quality standards relating to all essential features of the subject matter of the contract.3 The Contracting Authority requires that the offered medicinal products:1) be admitted to trading on the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001. Pharmaceutical Law;2) were registered in the Official List of Medicinal Products Authorized for Marketing on the territory of the Republic of Poland;3) had a certificate of authorization for marketing and a current Safety Data Sheet of the medicinal product;4) were reimbursed medicines with the EAN code or another code corresponding to the EAN code, contained in the announcement of the Minister of Health, valid as of the day of submission of offers, containing a list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices, and contained in the catalogue of reimbursed medicines used in chemotherapy, compliant with the annex to the regulation of the President of the National Health Fund, valid as of the day of submission of offers.4The conditions for the performance of the contract are also specified in the draft contract in Chapter XVII of the ToR. The subject matter of the contract is the successive supply of a medicinal product used in chemotherapy for patients of the Provincial Specialist Hospital in Legnica, described in detail in Attachment No. 2A to the Sizes, which constitutes its integral part.2Quality standards referred to in Art. 91 sec. 2a of the PPL - The Contracting Authority requires the supply of medicinal products with a strictly defined qualitative and quantitative composition - The subject matter of the contract has been described using quality standards relating to all material features of the subject matter of the contract.3 The Contracting Authority requires that the offered medicinal products:1) be authorised for marketing in Poland, in accordance with the provisions of the Act of 6 September 2001 in force in this respect. Pharmaceutical Law.24) were reimbursed medicines with EAN code or another code corresponding to EAN code, contained in the announcement of the Minister of Health, valid as of the date of submission of offers, containing a list of reimbursed medicines, foodstuffs for special nutritional uses and medical devices, and contained in the catalogue of reimbursed medicines used in chemotherapy, compliant with the annex to the regulation of the President of the National Health Fund4, valid as of the date of submission of offers. The conditions for the performance of the contract are also specified in the draft contract in Chapter XVII siwz. The subject matter of the contract is the successive supply of a medicinal product used in chemotherapy for patients of the Provincial Specialist Hospital in Legnica, described in detail in Attachment No. 2A to the Sizes, which constitutes its integral part.2Quality standards referred to in Art. 91 sec. 2a of the PPL - The Contracting Authority requires the supply of medicinal products with a strictly defined qualitative and quantitative composition - The subject matter of the contract has been described using quality standards relating to all material features of the subject matter of the contract.3 The Contracting Authority requires that the offered medicinal products:1) be authorised for marketing in Poland, in accordance with the provisions of the Act of 6 September 2001 in force in this respect. Pharmaceutical Law.2) were registered in the Official List of Medicinal Products Authorized for Marketing in the Republic of Poland; 3) had a certificate of authorization for marketing and a current Safety Data Sheet of the medicinal product; 4) The conditions of order performance were also specified in the draft agreement in Chapter XVII of the Harmonized System.

Opportunity closing date

19 June 2019

Value of contract

to be confirmed